二、关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说 明和独立意见 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要 求》《深圳证券交易所股票上市规则》的有关规定，对公司 2023 年上半年公司与 关联方的资金往来和对外担保进行了核查，发表专项说明和独立意见如下： 青岛三柏硕健康科技股份有限公司 独立董事关于第一届董事会第十七次会议 相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《青岛三柏硕健康科技股份有限公司章程》及 《青岛三柏硕健康科技股份有限公司独立董事工作制度》等有关规定，作为青岛 三柏硕健康科技股份有限公司（以下简称"公司"）的独立董事，对第一届董事 会第十七次会议相关事项进行了审议，并发表独立意见如下： 一、关于 2023 年半年度募集资金存放与使用情况的专项报告的独立意见 经核查，我们认为公司编制的《2023 年半年度募集资金存放与使用情况的 专项报告》真实、准确、完整地反映了公司 2023 年半年度募集资金的存放与实 际使用情况；2023 年半年度公司募集资金的存放与使用情况符合中国证 ...

证券代码：001300 证券简称：三柏硕 公告编号：2023-037 青岛三柏硕健康科技股份有限公司 第一届监事会第十六次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。 二、审议通过议案二：《2023 年半年度募集资金存放与使用情况的专项报 告》 表决情况：3票同意，0票反对，0票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023年 半年度募集资金存放与使用情况的专项报告》（公告编号：2023-038）。 三、备查文件 青岛三柏硕健康科技股份有限公司第一届监事会第十六次会议决议。 特此公告！ 青岛三柏硕健康科技股份有限公司 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第一届监事会第十 六次会议于 2023 年 8 月 29 日以现场和通讯方式召开，会议通知于 2023 年 8 月 19 日以专人送达、通讯、邮件等形式送达。会议应出席监事 3 名，实际出席监事 3 名。会议由监事长郑增建先生召集并主持，会议的召集、召开符合有关法律、 法规及《青岛三柏硕健康科技股份有限公司章程》的规定。与会监事经过 ...

证券代码：001300 证券简称：三柏硕 公告编号：2023-038 青岛三柏硕健康科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 青岛三柏硕健康科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 一、募集资金基本情况 （一）实际募集资金金额和资金到位时间 经中国证券监督管理委员会《关于核准青岛三柏硕健康科技股份有限公司首次公开发行 股票的批复》（证监许可[2022]2054号）核准，青岛三柏硕健康科技股份有限公司（以下简 称"三柏硕"或"公司"）向社会公开发行人民币普通股（A股）60,943,979股，每股面值1元， 每股发行价格11.17元，募集资金总额人民币680,744,245.43元，扣除各项发行费用合计人民 币70,090,350.29元，实际募集资金净额为610,653,895.14元。截至2022年10月14日止，实际募 集资金净额610,653,895.14元已全部到位，上述募集资金到位情况已经和信会计师事务所（特 殊普通合伙）出具和信验字（2022）第000046号《验资报告》验证。公司开设专户存储上述 募集资金。 （二）募集资金使用和结余情况 截至 ...

表决情况：7票同意，0票反对，0票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年 半年度募集资金存放与使用情况的专项报告》（公告编号：2023-038）。 证券代码：001300 证券简称：三柏硕 公告编号：2023-036 青岛三柏硕健康科技股份有限公司 第一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）第一届董事会第十 七次会议于 2023 年 8 月 29 日以现场和通讯方式召开，会议通知于 2023 年 8 月 19 日以专人送达、通讯、邮件等形式送达。会议应出席董事 7 名，实际出席董事 7 名。本次会议由董事长朱希龙先生主持。会议的召集、召开符合《中华人民共 和国公司法》等法律、法规及《青岛三柏硕健康科技股份有限公司章程》的规定。 公司监事、高管列席本次会议。 与会董事对本次会议的全部议案进行了充分讨论，审慎表决，形成如下决议： 一、审议通过议案一：《2023 年半年度报告及其摘要》 表决情况：7票同意，0票反对，0 ...

证券代码： 001300 证券简称：三柏硕 青岛三柏硕健康科技股份有限公司 投资者关系活动记录表 业绩表现略有改善。感谢您的关注！ 2、为啥一季度业绩这么差？ 尊敬的投资者，您好！2023 年度第一季度公司利润较上年 同期下滑的主要原因是：（1）2022 年一季度居家休闲健身及相 关采购需求较高，同时因海运较为紧张，全球主要运动器材品牌 商及零售商大规模备货，因此 2022 年一季度营业收入较高；（2） 在国际市场，受通胀高企、需求复苏缓慢等因素影响，导致公司 订单不足，工厂阶段性开工率低，对公司经营业绩造成了不利影 响。(3）环比 2022 年第四季度，公司 2023 年第一季度单季度的 业绩表现略有改善。感谢您的关注！ 3、能说明一下一季度业绩下滑 90%的原因，对今年的整体业 绩是否有影响，公司有什么应对策略？ 尊敬的投资者，您好！2023 年度第一季度公司利润较上年 同期下滑的主要原因是：（1）2022 年一季度居家休闲健身及相 关采购需求较高，同时因海运较为紧张，全球主要运动器材品牌 商及零售商大规模备货，因此 2022 年一季度营业收入较高；（2） 在国际市场，受通胀高企、需求复苏缓慢等因素影响， ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 青岛三柏硕健康科技股份有限公司（以下简称"公司"）《2022年年度报告》 已于2023年4月28日在巨潮资讯网（www.cninfo.com.cn）披露，同日《2022年年度 报告摘要》已在指定信息披露媒体《中国证券报》《证券时报》《证券日报》《上 海证券报》《经济参考报》和巨潮资讯网（www.cninfo.com.cn）披露。为帮助广 大投资者更深入、全面地了解公司2022年年度报告的相关情况，公司将举办2022 年度网上业绩说明会，现将有关事项公告如下： 一、召开时间：2023年5月17日（星期三）15:00-17:00 二、召开方式：本次年度业绩说明会将采用全景网平台网络远程的方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 业绩说明会。 三、出席人员：董事长兼总经理朱希龙先生、独立董事鲍在山先生、财务总 监蓝华女士、董事会秘书方瑞征先生、保荐代表人赵凤滨女士（如有特殊情况， 参与人员相应调整）。 证券代码：001300 证券简称：三柏硕 公告编号：2 ...

Financial Performance - The company's operating revenue for 2022 was CNY 567.13 million, a decrease of 53.01% compared to the previous year[28]. - The net profit attributable to shareholders for 2022 was CNY 65.70 million, down 48.87% year-over-year[28]. - The company's operating profit for 2022 was CNY 72.48 million, reflecting a decline of 52.96% from the previous year[39]. - The cash flow from operating activities for 2022 was CNY 58.08 million, a decrease of 59.18% compared to 2021[28]. - The total assets at the end of 2022 amounted to CNY 1,262.38 million, an increase of 42.32% from the end of 2021[28]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,091.21 million, up 171.29% from the end of 2021[28]. - The basic earnings per share for 2022 were CNY 0.3404, a decrease of 51.57% compared to 2021[28]. - In 2022, the company's total operating revenue was CNY 56,713.32 million, a decrease of 53.01% compared to the previous year[87]. - The net profit attributable to shareholders was CNY 6,570.16 million, down 48.87% year-on-year[87]. - The trampoline segment generated CNY 275,700.43 million, representing 48.61% of total revenue, with a decline of 60.89% compared to 2021[88]. - Fitness equipment revenue was CNY 118,330.97 million, accounting for 20.86% of total revenue, down 59.54% year-on-year[88]. - North America contributed CNY 260,106.80 million, which was 45.86% of total revenue, reflecting a 61.36% decrease from the previous year[88]. Market Strategy and Expansion - The company is focused on expanding its market presence and developing new products and technologies to meet consumer demands[1]. - The company aims to become a leader in the trampoline sector and a well-known provider of comprehensive health solutions[39]. - The company plans to focus on maintaining and developing key customer groups in critical markets as the inflationary pressures are expected to ease with monetary policy adjustments by central banks[41]. - The company aims to leverage its supply chain advantages and product innovation to achieve its operational performance goals in the coming year[41]. - The company is actively expanding its domestic market for leisure sports and fitness equipment, in addition to its international efforts[74]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 500 million RMB allocated for this purpose[168]. - The company plans to enhance its digital marketing strategy, aiming for a 50% increase in online sales channels by the end of 2023[157]. - The company is expanding its market presence, targeting a 30% increase in market share in the Asia-Pacific region by the end of 2023[159]. Product Development and Innovation - The company has approximately 31 product series and over 1,000 products in its portfolio, focusing on leisure sports and fitness equipment[74]. - The company has invested in R&D, resulting in 167 patents, including 7 invention patents, to support innovation in product development[80]. - The company emphasizes the integration of new technologies in product development, focusing on aesthetics, ergonomics, and smart features[71]. - The company is developing a new Olympic trampoline with innovative materials expected to launch in 2023, aiming to enhance product variety and market share[100]. - The company plans to launch the EZ-SKY series trampoline in 2023, focusing on improving product safety and user experience through advanced material research[101]. - The company is enhancing its product line with a new home-use folding trampoline, which will optimize space and improve market competitiveness[102]. - The company aims to improve brand recognition and market share by launching new products that meet consumer demands and enhance user convenience[101]. - The company is committed to comprehensive intelligent upgrades of its products through deepening technological innovation[191]. Corporate Governance and Transparency - The company is committed to transparency and has made its annual report available through designated media outlets[6]. - The company is focused on maintaining transparency and compliance with regulatory requirements through regular shareholder meetings[152]. - The company is committed to enhancing its corporate governance by appointing independent directors and auditors as part of its strategy[154]. - The company has outlined its plans for future financial management and investment strategies in the 2022 financial budget[152]. - The audit committee held multiple meetings to review and approve the 2021 annual financial report and the 2022 annual financial budget proposal[179]. - The company has established a management system for foreign exchange derivative trading to effectively control trading risks[122]. Risks and Challenges - The company acknowledges potential risks in its future development, which are detailed in the management discussion and analysis section of the report[6]. - The company faced significant pressure in domestic and international operations due to external environmental factors in 2022[39]. - High reliance on overseas markets poses risks due to potential changes in export policies, transportation, and political environments, which could adversely affect sales and profitability[136]. - Currency fluctuation risks are significant as the company primarily exports to North America and Europe, with USD as the main settlement currency[139]. - Global market uncertainties, including high inflation and geopolitical conflicts, may lead to decreased purchasing power in key markets, affecting overall performance[140]. Employee and Labor Management - The total number of employees at the end of the reporting period was 1,074, with 599 in the parent company and 475 in major subsidiaries[183]. - The company has established a performance-based salary system to attract and retain talent, with annual salary adjustments based on market research[184]. - The company has developed a detailed annual training plan to enhance employee skills and capabilities[185]. - The company has a total of 18 employees with a master's degree or higher, indicating a focus on educational diversity within the workforce[183]. Financial Management and Investments - The company plans to apply for credit and financing from financial institutions in 2022, as approved in the annual shareholder meeting[152]. - The total investment amount for the reporting period was CNY 74.69 million, indicating a 100% increase compared to the previous year[117]. - The company has committed to a total investment of CNY 61,065 million, with actual investment amounting to CNY 7,469.4 million, representing approximately 12.2% of the total commitment[128]. - The company has not reported any changes in the use of raised funds during the reporting period[131]. Customer and Supplier Relationships - The company has established strong partnerships with international retailers such as Amazon, Walmart, Decathlon, and Reebok, enhancing its market presence[74]. - The total sales amount from the top five customers is ¥411,251,100.46, accounting for 72.51% of the annual total sales[97]. - The total procurement amount from the top five suppliers is ¥90,187,875.77, which accounts for 35.83% of the annual total procurement[98]. Sustainability and Social Responsibility - The company is committed to sustainability initiatives, aiming to reduce operational carbon emissions by 25% by 2025[161]. - The management team emphasized a focus on sustainability, with plans to implement eco-friendly practices across all operations by the end of 2023[168].

Financial Performance - The company's revenue for Q1 2023 was ¥102,804,724.14, a decrease of 59.33% compared to ¥252,796,801.73 in the same period last year[5] - Net profit attributable to shareholders was ¥3,825,378.02, down 90.32% from ¥39,505,342.74 year-on-year[5] - Basic and diluted earnings per share were both ¥0.0157, reflecting a decline of 92.73% from ¥0.2161 in the prior year[5] - The company reported a significant drop in operating costs, which were ¥81,680,989.89, down 53.83% from ¥176,906,963.74 year-on-year[9] - Total operating revenue for Q1 2023 was ¥102,804,724.14, a decrease of 59.4% compared to ¥252,796,801.73 in the same period last year[19] - Net profit for Q1 2023 was ¥3,825,378.02, a decline of 90.3% from ¥39,505,342.74 in Q1 2022[21] - Other comprehensive income after tax for Q1 2023 was -¥2,229,835.96, compared to -¥585,853.57 in Q1 2022[21] - The company reported a total comprehensive income of ¥1,595,542.06 for Q1 2023, down from ¥38,919,489.17 in the same period last year[21] Cash Flow and Investments - The net cash flow from operating activities improved by 18.25%, reaching -¥25,016,820.90 compared to -¥30,601,860.28 in the previous year[5] - Cash flow from investment activities showed a significant inflow of ¥681,486,480.31, primarily due to the redemption of financial products[9] - Total cash inflow from investment activities was 681,655,138.67, while cash outflow was 705,011,803.12, resulting in a net cash flow of -23,356,664.45 for Q1 2023[23] - The net cash flow from financing activities was -8,153,326.70, compared to a positive cash flow of 75,035,614.60 in Q1 2022[23] - The total operating cash inflow for Q1 2023 was 89,659,086.71, significantly lower than 181,489,990.37 in Q1 2022[23] - The total operating cash outflow for Q1 2023 was 114,675,907.61, compared to 212,091,850.65 in Q1 2022, showing a reduction in cash outflow[23] - The company received tax refunds amounting to 12,349,828.46 in Q1 2023, compared to 18,213,609.79 in Q1 2022[23] - Cash paid to employees in Q1 2023 was 33,758,999.72, down from 43,529,141.18 in Q1 2022[23] - The company reported cash inflow from the disposal of fixed assets and other long-term assets of 168,658.36 in Q1 2023, compared to 96,719.90 in Q1 2022[23] - The company’s cash flow from other operating activities was 8,651,746.07 in Q1 2023, compared to 6,249,507.95 in Q1 2022, indicating an increase[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,232,789,572.28, a decrease of 2.34% from ¥1,262,376,318.93 at the end of the previous year[5] - The total liabilities decreased from ¥1,031,882,073.67 to ¥1,004,011,846.32 in current assets[16] - The total liabilities as of Q1 2023 were ¥139,987,080.37, a decrease of 18.1% from ¥171,169,369.08 in the previous year[20] - Cash and cash equivalents at the end of the reporting period amounted to ¥237,335,633.44, down from ¥292,957,753.49 at the beginning of the year[16] - The total number of common shareholders at the end of the reporting period was 24,961[12] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of the shares, totaling 115,317,531 shares[12] - The total assets of the company as of April 27, 2023, were ¥1,232,789,572.28, a decrease from ¥1,262,376,318.93 at the beginning of the year[16] Research and Development - Research and development expenses decreased by 35.74% to ¥4,155,128.57 from ¥6,465,948.22 in the same period last year[9] - The company plans to enhance R&D capabilities and expand its market presence to improve competitiveness and achieve sustainable growth[14] - Research and development expenses for Q1 2023 were ¥4,155,128.57, down 35.8% from ¥6,465,948.22 in the same period last year[20] Future Outlook and Strategy - The company experienced a slight improvement in performance compared to Q4 2022, despite ongoing challenges in the external environment[14] - The company aims to implement a long-term incentive mechanism to retain core talent and share business growth[14] - The company experienced a 52.87% decline in cash received from sales, totaling ¥76,116,155.63, down from ¥161,498,027.63 year-on-year[9] - The company's accounts receivable increased to ¥123,536,780.87 from ¥98,531,477.31[16]

Financial Performance - The company's revenue for Q3 2022 was ¥123,632,259.92, a decrease of 57.83% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥23,614,385.53, down 34.91% year-on-year[5] - The basic earnings per share for Q3 2022 was ¥0.13, reflecting a decline of 34.91% compared to the previous year[5] - The company experienced a 47.08% decline in total revenue year-to-date, totaling ¥527,499,913.42, primarily due to reduced sales volume[10] - Total operating revenue for the current period is ¥527,499,913.42, a decrease of 47% compared to ¥996,873,982.72 in the previous period[18] - Net profit for the current period is ¥94,955,994.70, a decline of 25% from ¥126,464,237.72 in the previous period[19] - Basic and diluted earnings per share are both ¥0.52, compared to ¥0.69 in the previous period[20] - Total comprehensive income for the current period is ¥119,796,243.86, compared to ¥125,043,625.02 in the previous period[19] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥694,609,470.31, a decrease of 21.69% from the end of the previous year[5] - The company's total assets as of September 30, 2022, amount to ¥694,609,470.31, a decrease from ¥887,005,037.95 at the beginning of the year[16] - Current assets decreased to ¥476,089,675.02 from ¥671,221,578.76 at the beginning of the year, reflecting a decline of approximately 29%[15] - Cash and cash equivalents decreased to ¥160,650,861.00 from ¥320,333,416.21, a reduction of about 50%[15] - Total liabilities decreased to ¥172,581,907.38 from ¥484,773,718.88, indicating a significant reduction in liabilities[17] - The company's equity attributable to shareholders increased to ¥522,027,562.93 from ¥402,231,319.07, showing a growth of approximately 30%[17] Cash Flow - The cash flow from operating activities for the year-to-date was ¥121,463,060.34, a slight decrease of 3.21%[5] - Cash flow from operating activities is ¥121,463,060.34, slightly down from ¥125,492,914.66 in the previous period[20] - The net cash flow from financing activities was negative at -¥231,646,044.21, primarily due to loan repayments[10] - The net cash flow from investment activities was -30,354,937.83, compared to -27,206,194.62 in the previous period, indicating an increase in cash outflow by approximately 8.0%[21] - The total cash inflow from financing activities was 165,311,239.11, down from 382,852,789.87, representing a decrease of about 56.8%[21] - Cash outflow for debt repayment was 352,327,536.00, which increased from 216,000,000.00, marking a rise of approximately 63.3%[21] - The net increase in cash and cash equivalents was -127,032,851.82, compared to -60,046,266.51, indicating a worsening of approximately 111.1%[21] - The ending balance of cash and cash equivalents was 155,765,216.59, down from 237,406,293.18, representing a decrease of about 34.3%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5, with no preferred shareholders[11] - The largest shareholder, Qingdao Haishuo Health Industry Development Co., Ltd., holds 47.30% of shares, totaling 115,317,531 shares[11] - The company has not yet completed its initial public offering, thus there are no unrestricted shareholders[11] - The company completed its initial public offering of 60,943,979 shares on October 19, 2022[13] Other Financial Metrics - The company reported a significant increase in trading financial assets, rising by 632.58% to ¥60,134,653.94 due to the purchase of structured deposits[9] - The company received government subsidies amounting to ¥14,983,190.47 year-to-date, an increase of 366.93% compared to the previous year[10] - The company reported a net profit of ¥242,967,113.50 in retained earnings, up from ¥148,011,118.80, indicating a strong performance in profitability[17] - Total operating costs for the current period are ¥430,763,438.09, down 49% from ¥853,167,225.43 in the previous period[18] - Other income increased to ¥14,983,190.47 from ¥3,208,869.00 in the previous period, showing a significant growth[18] - Investment loss for the current period is ¥6,361,368.24, compared to a gain of ¥3,263,311.43 in the previous period[18] - Sales expenses decreased to ¥21,937,904.67 from ¥32,191,950.78, reflecting a cost-cutting strategy[18] - Research and development expenses are ¥17,813,563.71, slightly down from ¥18,843,020.64 in the previous period, indicating stable investment in innovation[18] Audit Information - The company did not undergo an audit for the third quarter report[22]